GcMAF (Macrophage Activation)
The Gc-protein-derived Macrophage Activating Factor (GcMAF) is an immunotherapy that is often used in strong diseases like cancer. GcMAF activates the immune system and helps the body to recognize cancer cells and fight against them. GcMAF is an isoelectric focusing pattern and tumoricidal activity.
GcMAF Serum Gc protein (known as vitamin D3-binding protein) is the precursor for the principal macrophage activating factor (MAF). It is being tested for use in cancer and HIV treatment. Gc protein is the precursor for GcMAF, with three phenotypes: Gc1f, Gc1s, and Gc2, based on its electrophoretic mobility. The difference in electrophoretic mobility is because of the difference in its posttranslational sugar moiety composition. We compared the difference between Gc protein and GcMAF electrophoretic mobility using the isoelectric focusing (IEF) method. The tumoricidal activity of GcMAF-treated macrophage was evaluated after co-culture with L-929 cell.
The tumoricidal mechanism was investigated using TNF bioassay and nitric oxide (NO) release. The difference in Gc protein and GcMAF electrophoretic mobility was detected. The tumoricidal activity of GcMAF-treated macrophage was detected, but no release of TNF or NO was detected. The difference of isoelectric focusing mobility in Gc protein and GcMAF would be useful to develop a GcMAF detection method. GcMAF increased macrophage tumoricidal activity but TNF and NO release were not involved in the mechanism.
GcMAF is administered only by intravenous injection, because scientifically proven subcutaneous or intramuscular injections do not exist. An oral intake of GcMAFs leads to complete degradation of the active substance on the first pass effect of the digestive system. The dosage of the immune treatment is individually adapted to the patient.
Very good results of GcMAF treatment can be observed in a 3-month-period.
GcMAF is used in the treatment of: